about
Rapgef2 connects GPCR-mediated cAMP signals to ERK activation in neuronal and endocrine cellsThe dynamic nature of the kinomeRal GTPases in tumorigenesis: emerging from the shadowsC-Raf deficiency leads to hearing loss and increased noise susceptibility.Muscle-derived extracellular signal-regulated kinases 1 and 2 are required for the maintenance of adult myofibers and their neuromuscular junctions.In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma.RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation.MAPK1 is required for establishing the pattern of cell proliferation and for cell survival during lens development.Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway.Roles of Vitamin A Metabolism in the Development of Hepatic Insulin Resistance.Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Molecular controls of arterial morphogenesis.The nuclear translocation of ERK1/2 as an anticancer target.Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells.MicroRNA-9-5p functions as a tumor suppressor in papillary thyroid cancer via targeting BRAF
P2860
Q24296811-2878A7E3-BB48-419F-AAAE-E33324C6E9A3Q26852588-435926C4-CF91-4663-9E32-2C3C289D0B2DQ28294053-67CD0C5E-4BBC-4DD5-A39B-5D18FE760C48Q30664961-B1A86885-49EB-4EFA-A43F-1E1E58190AA9Q35165138-E39CC889-1D91-44AF-9EDE-2F1714824126Q35506764-387A0508-18BF-43D3-9F3C-5B7490D485EEQ36216004-281381F2-E8A6-4F13-BD5B-6BE35ECEA2C1Q36579425-1A02931C-57F5-4A24-9695-1298AEB967DFQ36682984-A1CF6227-F3C5-4399-AC9A-F8BFC9194403Q36685199-F7ED6837-0FB0-4F68-A6A8-21B77FAE3155Q36962066-D73A5EE0-FAB1-4A02-85BE-2341A2D6BA36Q37482888-C7B131AD-8D0B-4BE6-B727-043A33470377Q38397326-99289C38-A69F-41B8-9339-CE903C6B00AFQ38466556-12BA5AD8-3F22-499E-A4F5-EA97CEF8D1C7Q38893704-36070AD8-DA38-4441-8EA8-B3C2441C3995Q50909347-399ABFC6-66ED-452F-A247-336D98482A80Q51328396-D559D892-8AA5-4FDD-835A-B26458B0A5C1Q58573121-14449D5B-7A33-4617-ADDF-2907099EC7B7
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Signal control through Raf: in sickness and in health.
@en
Signal control through Raf: in sickness and in health.
@nl
type
label
Signal control through Raf: in sickness and in health.
@en
Signal control through Raf: in sickness and in health.
@nl
prefLabel
Signal control through Raf: in sickness and in health.
@en
Signal control through Raf: in sickness and in health.
@nl
P2860
P356
P1433
P1476
Signal control through Raf: in sickness and in health.
@en
P2093
Elma Zaganjor
Jihan K Osborne
P2860
P2888
P356
10.1038/CR.2011.193
P577
2011-12-06T00:00:00Z